Lung Cancer Targeting Efficiency of Silibinin Loaded Poly Caprolactone /Pluronic F68 Inhalable Nanoparticles: In Vitro and In Vivo Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 May 13

PMID 35560136

Authors

Priya Patel

Mihir Raval

Aneka Manvar

Vishal Airao

Vaibhav Bhatt

Pranav Shah

Affiliations

Soon will be listed here.

Abstract

Silibinin (SB) is shown to have an anticancer properties. However, its clinical therapeutic effects have been restricted due to its low water solubility and poor absorption after oral administration. The aim of this study was to develop SB-loaded PCL/Pluronic F68 nanoparticles for pulmonary delivery in the treatment of lung cancer. A modified solvent displacement process was used to make nanoparticles, which were then lyophilized to make inhalation powder, Nanoparticles were characterized with DSC, FTIR,SEM and In vitro release study. Further, a validated HPLC method was developed to investigate the Biodistribution study, pharmacokinetic parameters. Poly Caprolactone PCL / Pluronic F68 NPs showed the sustained release effect up to 48 h with an emitted (Mass median Aerodynamic diameter)MMAD and (Geometric size distribution)GSD were found to be 4.235 ±0.124 and 1.958±1.23 respectively. More specifically, the SB Loaded PCL/Pluronic F 68 NPs demonstrated long circulation and successful lung tumor-targeting potential due to their cancer-targeting capabilities. SB Loaded PCL/Pluronic F68 NPs significantly inhibited tumour growth in lung cancer-induced rats after inhalable administration. In a pharmacokinetics study, PCL/ Pluronic F68 NPs substantially improved SB bioavailability, with a more than 4-fold rise in AUC when compared to IV administration. These findings indicate that SB-loaded PCL/PluronicF68 nanoparticles may be a successful lung cancer therapy delivery system.

Citing Articles

Silymarin: a promising modulator of apoptosis and survival signaling in cancer.

Sharma U, Sahni P, Sharma B, Gupta M, Kaur D, Mathkor D Discov Oncol. 2025; 16(1):66.

PMID: 39836338 PMC: 11751200. DOI: 10.1007/s12672-025-01800-3.

Silibinin-Loaded Amphiphilic PLGA-Poloxamer Nanoparticles: Physicochemical Characterization, Release Kinetics, and Bioactivity Evaluation in Lung Cancer Cells.

Villapiano F, Piccioni M, DAria F, Crispi S, Rassu G, Giunchedi P Materials (Basel). 2024; 17(22).

PMID: 39597304 PMC: 11595691. DOI: 10.3390/ma17225480.

Emerging Nanomedicine Approaches in Targeted Lung Cancer Treatment.

Alexandru I, Davidescu L, Motofelea A, Ciocarlie T, Motofelea N, Costachescu D Int J Mol Sci. 2024; 25(20).

PMID: 39457017 PMC: 11508987. DOI: 10.3390/ijms252011235.

Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.

Kassaee S, Richard D, Ayoko G, Islam N Nanomedicine (Lond). 2024; 19(25):2113-2133.

PMID: 39143915 PMC: 11486133. DOI: 10.1080/17435889.2024.2387530.

The silibinin-loaded Zein-β cyclodextrin nano-carriers (SZBC-NCs) as a novel selective cancer cell drug delivery system in HT-29 cell line.

Al Alabdullah M, Goodarzi M, Homayouni Tabrizi M Sci Rep. 2024; 14(1):14769.

PMID: 38926533 PMC: 11208413. DOI: 10.1038/s41598-024-65881-w.

References

Zou J, Su S, Chen Z, Liang F, Zeng Y, Cen W . Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy. Artif Cells Nanomed Biotechnol. 2019; 47(1):3456-3464. DOI: 10.1080/21691401.2019.1626863. View

Joshi S, Chavhan S, Sawant K . Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010; 76(2):189-99. DOI: 10.1016/j.ejpb.2010.07.007. View

Mahaffey C, Davies A, Lara Jr P, Pryde B, Holland W, Mack P . Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2008; 8(9):548-53. DOI: 10.3816/clc.2007.n.041. View

Al-Anati L, Essid E, Reinehr R, Petzinger E . Silibinin protects OTA-mediated TNF-alpha release from perfused rat livers and isolated rat Kupffer cells. Mol Nutr Food Res. 2009; 53(4):460-6. DOI: 10.1002/mnfr.200800110. View

Singh B, Kumar R, Ahuja N . Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst. 2005; 22(1):27-105. DOI: 10.1615/critrevtherdrugcarriersyst.v22.i1.20. View

Nguyen J, Xie X, Neu M, Dumitrascu R, Reul R, Sitterberg J . Effects of cell-penetrating peptides and pegylation on transfection efficiency of polyethylenimine in mouse lungs. J Gene Med. 2008; 10(11):1236-46. DOI: 10.1002/jgm.1255. View

Roa W, Azarmi S, Al-Hallak M, Finlay W, Magliocco A, Lobenberg R . Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release. 2010; 150(1):49-55. DOI: 10.1016/j.jconrel.2010.10.035. View

Sun H, Mei L, Song C, Cui X, Wang P . The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2005; 27(9):1735-40. DOI: 10.1016/j.biomaterials.2005.09.019. View

Fonseca C, Simoes S, Gaspar R . Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release. 2002; 83(2):273-286. DOI: 10.1016/s0168-3659(02)00212-2. View

10.

Abdallah M, Lila A, Unissa R, Elsewedy H, Elghamry H, Soliman M . Brucine-Loaded Ethosomal Gel: Design, Optimization, and Anti-inflammatory Activity. AAPS PharmSciTech. 2021; 22(8):269. DOI: 10.1208/s12249-021-02113-8. View

11.

Lemjabbar-Alaoui H, Hassan O, Yang Y, Buchanan P . Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015; 1856(2):189-210. PMC: 4663145. DOI: 10.1016/j.bbcan.2015.08.002. View

12.

Zhao J, Castranova V . Toxicology of nanomaterials used in nanomedicine. J Toxicol Environ Health B Crit Rev. 2011; 14(8):593-632. DOI: 10.1080/10937404.2011.615113. View

13.

Kabanov A, Batrakova E, Alakhov V . Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. 2002; 54(5):759-79. DOI: 10.1016/s0169-409x(02)00047-9. View

14.

Ling Y, Li T, Yuan Z, Haigentz Jr M, Weber T, Perez-Soler R . Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell.... Mol Pharmacol. 2007; 72(2):248-58. DOI: 10.1124/mol.107.034827. View

15.

Ha E, Han D, Seo S, Kim J, Lee S, Sim W . A Simple HPLC Method for the Quantitative Determination of Silybin in Rat Plasma: Application to a Comparative Pharmacokinetic Study on Commercial Silymarin Products. Molecules. 2019; 24(11). PMC: 6600178. DOI: 10.3390/molecules24112180. View

16.

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

17.

Hogan F, Krishnegowda N, Mikhailova M, Kahlenberg M . Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 2007; 143(1):58-65. DOI: 10.1016/j.jss.2007.03.080. View

18.

Elamanchili P, McEachern C, Burt H . Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function. J Pharm Sci. 2008; 98(3):945-58. DOI: 10.1002/jps.21479. View

19.

Ravanfar R, Tamaddon A, Niakousari M, Moein M . Preservation of anthocyanins in solid lipid nanoparticles: Optimization of a microemulsion dilution method using the Placket-Burman and Box-Behnken designs. Food Chem. 2016; 199:573-80. DOI: 10.1016/j.foodchem.2015.12.061. View

20.

Betancourt T, Brown B, Brannon-Peppas L . Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond). 2007; 2(2):219-32. DOI: 10.2217/17435889.2.2.219. View